Hans Louis Jos de Winter
Keine laufenden Positionen mehr
Karriereverlauf von Hans Louis Jos de Winter
Ehemalige bekannte Positionen von Hans Louis Jos de Winter
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Direktor/Vorstandsmitglied | 10.05.2010 | 11.05.2012 |
Technik-/Wissenschafts-/F&E-Leiter | 01.01.2005 | 11.05.2012 | |
Gründer | 01.01.2005 | 11.05.2012 | |
Victoria University | Corporate Officer/Principal | - | - |
The Janssen Research Foundation | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1996 | - |
Ausbildung von Hans Louis Jos de Winter
Université Catholique de Louvain | Undergraduate Degree |
Statistik
International
Belgien | 3 |
Vereinigte Staaten | 2 |
Australien | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Director/Board Member | 1 |
Founder | 1 |
Sektoral
Consumer Services | 3 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Health Technology |
The Janssen Research Foundation |